TY - JOUR T1 - Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p3996 AU - Tetyana Pertseva AU - Kateryna Gashynova Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p3996.abstract N2 - Respiratory muscles dysfunction in patients with COPD could affect the inhalation technique and be one of the causes of ICS and brochodilator's inefficacy.Aim of study: To evaluate efficacy of Budesonide/Formoterol combination in dry powder inhaler (Symbicort, Astra Zeneca) in patients with COPD (stage III) with signs of respiratory muscles dysfunction.Study population and Methods: 20 patients with COPD III (17 men, mean age 58.9±6.3 yrs), who regularly treated by high doses of any ICS and bronchodilators no less than three month made the study sample. All patients were current smokers and had signs of respiratory muscles dysfunction (PImax ≤60 kPa).At baseline all patient withdrawn from their COPD therapy and were prescribed Budesonide/Formoterol combination 320/9 mcg BID.Pulmonary function tests (FEV1, MMLV), PImax, 6MWD and plasma C- reactive protein were evaluated before and 12 months after beginning of the study.Results: Results are present in Table 1.View this table:Conclusions: Long-term prescription of Budesonide/Formoterol combination in dry powder inhaler (Symbicort, Astra Zeneca) in COPD patients with signs of respiratory muscles dysfunction significantly increase their MMVL, exercises capacity and reduce respiratory muscles fatigue and systemic inflammation. ER -